New ADD Site Feasibility Platform Launched by TCS
IndraStra Open Journal Systems
IndraStra Global

New ADD Site Feasibility Platform Launched by TCS

By IndraStra Global News Team

Image Attribute:

On August 2, 2019, India's Tata Consultancy Services (TCS) has launched Advanced Drug Development (ADD) Site Feasibility Platform, which will provide "life sciences companies with a single, integrated platform that digitizes the site selection and activation processes, and facilitates data-driven decision-making while assessing site feasibility for multi-site clinical trials."

According to the company's statement, "In the planning of a clinical study, selection of the right sites for the clinical trials, with the right patient population, investigator profiles, treatment facilities, and other parameters, has a huge impact on the study outcomes. Earlier, this critical activity was done manually which resulted in significant delays and costs. TCS’s new feasibility platform addresses this critical problem which is faced by the life sciences companies."

The new platform consolidates data currently residing on multiple systems within the enterprise into a central knowledge repository from which it derives insights that can be used to identify the sites best suited for a given study protocol, with the most appropriate patient population and investigators. It digitizes and automates the entire assessment and selection process, enabling the efficient and coordinated management of hundreds of concurrent clinical trial feasibility studies. It also provides customers with an end-to-end solution for conducting site surveys and analyzing the survey responses.

“We are leveraging our deep knowledge of the life sciences industry to continually expand the capabilities of the TCS ADD suite of cloud platforms. The Site Feasibility platform will help our customers digitally transform the most critical study design aspects of their clinical trials and drive superior outcomes,” said Debashis Ghosh, President, Life Sciences and Healthcare, TCS.